ARF-BP1 as a potential therapeutic target
2006
ARF-BP1 as a potential therapeutic target
publication
Evidence: moderate
Author Information
Author(s): Chen D, Brooks C L, Gu W
Primary Institution: Institute for Cancer Genetics, Department of Pathology, College of Physicians & Surgeons, Columbia University
Hypothesis
ARF-BP1 emerges as a novel therapeutic target against cancer regardless of p53 status.
Conclusion
Inactivation of ARF-BP1 can induce growth arrest in cancer cells with mutant p53.
Supporting Evidence
- ARF-BP1 inactivation stabilised p53 and induced apoptosis in various cancer cell lines.
- ARF-BP1 is highly expressed in 80% of breast cancer cell lines.
- Inactivation of ARF-BP1 can inhibit cell growth in cancer cells with mutant p53.
Takeaway
ARF-BP1 is a protein that helps control another protein called p53, which is important for stopping cancer. If we can turn off ARF-BP1, it might help fight cancer better.
Methodology
The review discusses the role of ARF-BP1 in regulating p53 and its potential as a therapeutic target in cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website